Some Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Patients Respond Well to Tazemetostat in Phase 1 Trial
News
The investigational EZH2 inhibitor tazemetostat was safe and shrank tumors in 38 percent of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma who were included in the first part of a ... Read more